Amneal Secures FDA Nod for Romidepsin Injection, Gaining 180-Day Exclusivity — Amneal Pharmaceuticals, Inc.

Event summary

Amneal's romidepsin injection solution received FDA approval on June 4, 2026, offering a ready-to-use alternative to lyophilized powder.
The product qualifies for Competitive Generic Therapy (CGT) designation, granting Amneal 180 days of market exclusivity.
Romidepsin injection solution references a previously marketed formulation by Teva, which was withdrawn from the market.
The product is indicated for treating cutaneous T-cell lymphoma in adult patients who have received prior systemic therapy.
IQVIA reported U.S. annual sales for the referenced romidepsin lyophilized powder at approximately $78 million for the 12 months ended April 2026.

The big picture

Amneal's FDA approval for romidepsin injection solution underscores its leadership in complex generic therapies, with the CGT designation reinforcing its strategy of delivering high-value, differentiated products. The move aligns with broader industry trends toward ready-to-use formulations, which reduce preparation complexity and enhance patient safety. Amneal's growing injectables business positions it to strengthen supply reliability and expand access to critical oncology treatments.

What we're watching

Market Exclusivity: How Amneal will leverage its 180-day exclusivity to capture market share in the oncology segment.
Product Differentiation: Whether the ready-to-use formulation will drive adoption among hospitals and pharmacies.
Competitive Dynamics: The pace at which Amneal can expand its injectables portfolio following this approval.